Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.
Flexbumin 5% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for IV administration derived from human venous plasma using the Cohn cold ethanol fractionation process. Along with Flexbumin 25%, it is the first and only preparation of human albumin to be packaged in a flexible plastic container.
Flexbumin 5% will be available in a 250mL solution to customers later this year.
For more information visit Baxter.com.